News

Intellia Therapeutics to Showcase Significant Investor Insights

Intellia Therapeutics to Showcase Significant Investor Insights

Upcoming Investor Events from Intellia Therapeutics

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a pioneering company in the field of gene editing, has announced its participation in two significant investor events coming up this November. These events will provide vital insights into the company’s advancements in gene therapies and operational performance. Investors can look forward to exciting updates that reflect Intellia’s commitment to revolutionizing medicine through its innovative CRISPR-based approaches.

Third Quarter 2024 Financial Results Presentation

The first event is scheduled for November 7, where Intellia will present its third quarter financial results for 2024 at 8 a.m. ET. This presentation will cover not only the financial metrics but also operational highlights that underscore the company’s progress and future direction.

How to Join the Financial Call

Investors interested in joining the financial call should dial in approximately five minutes before the start time. U.S. callers can reach the conference by calling 1-833-316-0545, while international callers should use 1-412-317-5726. It’s essential for all participants to request access to the Intellia Therapeutics conference call when they connect.

Clinical Data Update on nexiguran ziclumeran

The second key event will take place on November 16 at 11 a.m. CT / 12 p.m. ET, featuring a webcast that will present new clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z), an investigational therapy for transthyretin (ATTR) amyloidosis. This event follows the company’s participation in the American Heart Association (AHA) Scientific Sessions, happening from November 16-18.

Understanding nexiguran ziclumeran

Nex-z represents a breakthrough therapy in the treatment landscape of ATTR amyloidosis. This innovative solution is engineered to provide a single-dose treatment option. Intellia is dedicated to developing and commercializing nex-z in collaboration with Regeneron, highlighting the synergy between the two companies in advancing gene editing technology.

Accessing the Webcast and Replay Options

For those looking to join the webcast on November 16, access will be available via Intellia’s website. Interested parties can visit their Events and Presentations page for the livestream and future updates. Additionally, a replay of both investor events will be made accessible on the company’s website for a minimum of 30 days following each presentation, allowing investors to catch up on what they may have missed.

About Intellia Therapeutics

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is at the forefront of the clinical-development landscape, utilizing advanced CRISPR technology. The company aims to change how we treat genetic diseases through its in vivo programs, which uniquely edit disease-causing genes directly within the human body. Meanwhile, its ex vivo approaches focus on modifying human cells outside of the body to tackle cancer and autoimmune conditions. Intellia's commitment to pioneering new treatments is reinforced by its strong scientific and clinical expertise.

Continuous Innovation and Collaboration

As the field of gene editing expands, Intellia is actively working on enhancing its CRISPR technologies. Their research not only aims to refine editing capabilities but also to improve delivery methods, unlocking the potential for transformative therapies and improved patient outcomes.

Frequently Asked Questions

What events will Intellia Therapeutics hold in November?

Intellia will present its third quarter financial results and provide an update on its clinical data from the Phase 1 study of nexiguran ziclumeran.

How can I participate in Intellia’s investor events?

Investors can join the calls by dialing the specified numbers and accessing the webcast through Intellia’s Events and Presentations page.

What is nexiguran ziclumeran's role in medical treatment?

Nex-z is an investigational gene editing therapy aimed at treating transthyretin (ATTR) amyloidosis, designed to be administered as a single-dose.

Where can I find information about Intellia’s research?

Intellia provides updates on its research projects and clinical advances on its official website.

How long will the replays of events be available?

Replays of both events will be available for at least 30 days, ensuring investors can stay informed.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

TRIMEDX Earns Spot in 2024 Inspiring Workplaces Rankings

Updated Category News Views 62

TRIMEDX Recognized as One of the Top Inspiring Workplaces TRIMEDX, a leading name in clinical asset management, has proudly claimed the 30th spot on the 2024 Global Top 100 Inspiring Workplaces list. This esteemed recognition highlights organizations that prioritize people-first practices and create outstanding workplace environments. A Global Overview The Inspiring...

Continue Reading
Triumvirate Environmental Secures Major Investment Boost

Updated Category News Views 326

Triumvirate Environmental Announces $1.8 Billion Valuation Triumvirate Environmental, a prominent name in environmental services, has recently received a significant growth investment from Berkshire Partners, a well-respected private equity firm. This monumental partnership has led to Triumvirate being valued at $1.8 billion, a testament to its strong market position and...

Continue Reading
Investing in MSCI: A Journey Over 15 Years Explained

Updated Category News Views 198

The Growth of MSCI Over 15 Years MSCI (NYSE: MSCI) has demonstrated impressive performance over the past decade and a half, significantly outperforming the market. With an annualized return of 20.17%, MSCI has amassed a market capitalization of $43.82 billion. This remarkable performance speaks volumes about the company’s solid market positioning and timely strategic...

Continue Reading
Deckers Outdoor Surges in Premarket Trading After Strong Earnings Report

Updated Category News Views 243

Deckers Outdoor Impresses with Strong Financial Results Shares of Deckers Outdoor Corporation (NYSE: DECK) have recently experienced a notable increase in value. This uplift can be attributed to the company's impressive second-quarter earnings, which surpassed analysts' expectations. The casual footwear and apparel retailer reported revenue of $1.31 billion, significantly...

Continue Reading
Vitrolife Group Secures Major Financing Through Nordic Banks

Updated Category News Views 190

Vitrolife AB Strengthens Financial Backbone Vitrolife AB (publ) has taken a significant step towards enhancing its financial foundation by renewing and signing a loan agreement worth EUR 300 million. This strategic financial maneuver includes both a term loan and a revolving credit facility, aimed at refinancing existing debt while also providing resources for general...

Continue Reading